Fenwick & West LLP advised Meril on the deal.
Judge Gilliam of the United States District Court for the Northern District of California granted Meril’s summary judgment motion of non-infringement with respect to all patent infringement claims filed against Meril by Edwards Lifesciences Corporation and Edwards Lifesciences, LLC against Meril’s Myval transcatheter heart valve. The Court rejected Edwards’ argument that the safe harbor exemption of 35 U.S.C. § 271(e)(1) did not apply because Meril’s activities were allegedly for a commercial purpose. The Court determined that Meril’s activities were all reasonably related to developing information for submission to the U.S. Food and Drug Administration and fell squarely within the safe harbor regardless of the purported purpose of those activities. The Court therefore concluded that Meril did not infringe Edwards’ patents.
Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease. The Company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences supplies its products worldwide.
Meril provides medical equipment. The Company offers cardiovascular, orthopedic, diagnostics, and surgical equipment. Meril Life Sciences serves customers worldwide.
The Fenwick team was included litigation partners David Hadden (Picture) and Melanie Mayer and associate Chieh Tung.
Law Firms: Fenwick & West LLP;
Clients: Meril Life Sciences;